Pfizer
EpiPen supply issues to continue indefinitely
While Pfizer is working to achieve ongoing availability, it reportedly cannot commit to a specific time when the supply constraint will be fully resolved Mylan/Alphapharm, the sponsor of EpiPens, has …
Why a drug treatment for dementia has eluded us
Pfizer has announced it will stop research into developing drugs to treat Alzheimer’s disease, after costly failed attempts over the past decade Jürgen Götz, Director, Clem Jones Centre for Ageing Dementia …
Mixup wasn’t us: Pfizer
Pfizer has confirmed that the Heparin-Lignocaine mixup occurred at one pharmacy, not its own facilities But the recall for Heparin Injection 5000 IU 5mL x 50 and Lignocaine Injection 1% …
Heparin and Lignocaine recall, isolated incident likely
The TGA and Pfizer are working on a recall for Heparin and Lignocaine ampoules following a reported product mix-up The TGA said in a statement on Monday (14 August) that …
Cap problem leads to recall
Anticonvulsant recalled due to issue with child-resistant caps Pfizer Australia, in consultation with the TGA, has initiated a recall for product correction for bottles of phenytoin 30 mg capsules, 100 …
Pressure mounts for lower vaccine prices
Last month, Médecins Sans Frontières (MSF) surprised Pfizer by refusing a donation of one million doses of the company’s pneumonia vaccine With high numbers of children who are not immunised against …
Switch hitters recognised
Some of the leading OTC sales and marketing campaigns were recognised at the Australian Self Medication Industry (ASMI) Diamond Awards dinner. Held in Sydney late last week, three categories of …
Pfizer unveils last phase of Adelaide hub
Pfizer has unveiled the final phase of its $21 million investment which it says will establish Adelaide as a global manufacturing hub for a medicine commonly used to treat complications …
Inflectra to be PBS listed from December
Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions.
ACCC okays Pfizer’s Hospira acquisition
The Australian Competition and Consumer Commission has announced that it will not oppose Pfizer Inc’s proposed $US17 billion acquisition of Hospira Inc. “Pfizer and Hospira are also the two largest …